OverviewSuggest Edit

AnaptysBio is a biotechnology company developing immunology therapeutic product candidates. It focuses on immune control mechanisms applicable to inflammation and immuno-oncology indications. The company offers ANB019, ANB030, and ANB032 antibody programs to address inflammatory disorders.
TypePublic
Founded2005
HQSan Diego, CA, US
Websiteanaptysbio.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Dec 2019)89(-8%)
Job Openings13
Revenue (FY, 2020)$75 M(+838%)
Share Price (May 2021)$26.1

Key People/Management at AnaptysBio

Hamza Suria

Hamza Suria

President and CEO, Director
Paul F. Lizzul

Paul F. Lizzul

Chief Medical Officer
Eric Loumeau

Eric Loumeau

Chief Operating Officer
Beth Mueller

Beth Mueller

Senior Vice President, Human Resources
Dennis Mulroy

Dennis Mulroy

Chief Financial Officer
Margaret Marino

Margaret Marino

Senior Vice President, Project Management
Show more

AnaptysBio Office Locations

AnaptysBio has an office in San Diego
San Diego, CA, US (HQ)
10421 Pacific Center Ct Suite 200
Show all (1)

AnaptysBio Financials and Metrics

AnaptysBio Revenue

AnaptysBio's revenue was reported to be $75 m in FY, 2020
USD

Revenue (Q1, 2021)

11.2m

Net income (Q1, 2021)

(18.2m)

EBIT (Q1, 2021)

(18.4m)

Market capitalization (14-May-2021)

714.3m

Closing stock price (14-May-2021)

26.1

Cash (31-Mar-2021)

284.1m

EV

430.5m
AnaptysBio's current market capitalization is $714.3 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

10.0m5.0m8.0m75.0m

General and administrative expense

9.3m15.5m16.1m18.9m

R&D expense

29.4m56.2m99.3m80.0m

Operating expense total

38.8m71.7m115.4m98.9m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

7.0m5.0m5.0m15.0m11.2m

General and administrative expense

2.1m2.4m2.4m3.9m3.8m4.0m4.1m4.3m3.8m4.3m4.7m4.8m5.4m

R&D expense

7.9m7.2m6.7m11.8m10.6m17.9m20.6m27.4m29.9m21.0m17.9m19.5m24.2m

Operating expense total

10.0m9.6m9.1m15.8m14.4m21.9m24.8m31.7m33.7m25.3m22.6m24.3m29.6m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

81.2m113.6m171.0m250.5m

Accounts Receivable

Prepaid Expenses

2.7m7.0m3.5m2.9m

Current Assets

252.7m434.2m377.7m396.6m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

96.8m30.8m26.7m69.5m57.1m293.4m105.9m146.6m182.9m165.3m221.2m209.2m284.1m

Accounts Receivable

5.0m5.0m5.0m1.2m

Prepaid Expenses

1.7m3.9m3.1m2.2m3.8m4.0m6.1m3.8m3.6m3.6m6.6m7.5m5.5m

Current Assets

110.2m115.8m120.3m251.9m271.8m503.0m421.9m431.0m424.6m371.1m384.5m345.8m387.1m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(30.1m)(61.7m)(97.3m)(19.9m)

Depreciation and Amortization

183.0k315.0k514.0k559.0k

Accounts Payable

2.2m7.1m14.5m(8.9m)

Cash From Operating Activities

(19.4m)(48.5m)(69.5m)(14.2m)
USDQ1, 2017

Financial Leverage

1.2 x
Show all financial metrics

AnaptysBio Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

AnaptysBio Online and Social Media Presence

Embed Graph

AnaptysBio News and Updates

AnaptysBio Announces Appointment of Oleg Nodelman to Board of Directors

SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the …

AnaptysBio Reports Imsidolimab POPLAR Phase 2 Clinical Trial in Moderate-to-Severe Palmoplantar Pustulosis (PPP) Did Not Meet Primary Endpoint

SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that…

AnaptysBio to Present at the 39th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that …

AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference

SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that …

AnaptysBio Announces Third Quarter 2020 Financial Results and Provides Pipeline Updates

SAN DIEGO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported operat…

AnaptysBio and GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration

SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that …
Show more

AnaptysBio Blogs

AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates

The post AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates appeared first on AnaptysBio.

AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates

Imsidolimab Phase 3 GPP trial anticipated to commence in mid-2021 following FDA end-of-Phase 2 meeting held during Q2 2021 JEMPERLI (dostarlimab), our PD-1 antagonist antibody partnered with GlaxoSmithKline (GSK), was approved for endometrial cancer in the US and EU during Q2 2021, earning $30

European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe

The post European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe appeared first on AnaptysBio.

FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Cancer

The post FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Cancer appeared first on AnaptysBio.

AnaptysBio Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Pipeline Updates

Positive topline data from GALLOP Phase 2 clinical trial of imsidolimab in moderate to severe generalized pustular psoriasis (GPP) announced in October 2020 , with Phase 3 trial initiation anticipated in mid-2021 Topline data from POPLAR Phase 2 imsidolimab clinical trial in palmoplantar pustulosis

GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient (dMMR) solid cancers at ASCO Gastrointestinal Cancers Symposium -- Data from GARNET cohort F shows a 38.7% objective response rate with dostarlimab in patients with dMMR advanced solid cancers

GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient (dMMR) solid cancers at ASCO Gastrointestinal Cancers Symposium -- Data from GARNET cohort F shows a 38.7% objective response rate with dostarlimab in patients with dMMR advanced solid cancers
Show more

AnaptysBio Frequently Asked Questions

  • When was AnaptysBio founded?

    AnaptysBio was founded in 2005.

  • Who are AnaptysBio key executives?

    AnaptysBio's key executives are Hamza Suria, Paul F. Lizzul and Eric Loumeau.

  • How many employees does AnaptysBio have?

    AnaptysBio has 89 employees.

  • What is AnaptysBio revenue?

    Latest AnaptysBio annual revenue is $75 m.

  • What is AnaptysBio revenue per employee?

    Latest AnaptysBio revenue per employee is $842.7 k.

  • Who are AnaptysBio competitors?

    Competitors of AnaptysBio include Gracell, PharmaEssentia and Verastem.

  • Where is AnaptysBio headquarters?

    AnaptysBio headquarters is located at 10421 Pacific Center Ct Suite 200, San Diego.

  • Where are AnaptysBio offices?

    AnaptysBio has an office in San Diego.

  • How many offices does AnaptysBio have?

    AnaptysBio has 1 office.